Delaware
|
0-32353
|
84-1475672
|
||
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1180
Avenue of the Americas
19th
Floor
New
York, NY
|
10036
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
|
Item 2.02
|
Results
of Operations and Financial
Condition
|
Item
9.01
|
Financial Statements
and Exhibits
|
(d)
|
Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Press
Release of the Company dated March 24,
2009
|
ZIOPHARM Oncology,
Inc.
|
||
By:
|
/s/
Richard Bagley
|
|
Date:
March 24, 2009
|
Name:
Richard Bagley
|
|
Title:
President, Chief Operating Officer and Chief Financial
Officer
|
Exhibit No.
|
Description
|
|
99.1
|
Press
Release of the Company dated March 24,
2009
|